Temozolomide

目录号:S1237 别名: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide(TMZ)是一种单功能的SN-1烷化剂,修饰DNA环上的氮原子以及环外氧基团。在生理pH值下,TMZ转化为活性产物MTIC、降解为methyldiazonium cation,后者再将甲基转移到DNA, 阻碍DNA复制启动,诱使细胞凋亡,是一种DNA损伤诱导剂。

规格 价格 库存 购买数量  
RMB 521.97 现货
RMB 574.37 现货
RMB 1411.95 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的6个实验数据:

  • C57BL/6 mice were implanted in the striatum with citrine-GL26-Cherry-HMGB1, which were stably transfected to express the YFP citrine and HMGB1 fused to red fluorescent protein cherry. Fourteen days later, they were treated with saline, Ad-TK+Ad-Flt3L, or Ad-TK+Ad-Flt3L+TMZ (temozolomide). Five days after treatment, the cellular location of cherry-HMGB1 in these cells was assessed by confocal microscopy. Arrows, tumor cells (green) with cytoplasmic HMGB1 (red).

    Clin Cancer Res 2014 20(6), 1555-65. Temozolomide purchased from Selleck.

    Talazoparib and temozolomide exhibit marked combinatorial efficacy in PDXs. A, Western blot against MGMT by near-infrared imaging in PDX models.

    Clin Cancer Res, 2017, 23(2):523-535. Temozolomide purchased from Selleck.

  • J Control Release, 2018, 269:245-257. Temozolomide purchased from Selleck.

    Viability of U87 cells(A) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs temozolomide (TMZ) and Bliss interaction index (B) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 400 μM TMZ(A) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-18.. Temozolomide purchased from Selleck.

  • Cells were plated and 12 h after plating were treated with MMF (5 µM), FTY720 (50 nM), Temozolomide (TMZ, 3 µM) or in combination as indicated for 12 h. Cell viability was assessed by live / dead assay.

    Cancer Biol Ther, 2014, 15(12):1646-57. Temozolomide purchased from Selleck.

    Establishment of TMZ-resistant (TR) GBM cell lines. a-d, Evaluation of temozolomide resistance in four glioblastoma cell lines. Cells were cultured in the presence of 5-600 μM of TMZ. A dose-dependent association between the survival rate of cells and TMZ concentration can be observed. Each group was cultured for 24 h in the presence of different concentrations of TMZ, followed by an evaluation of IC50 for TMZ inhibited growth in A172-TR/A172, U118-TR/U118, U251-TR/U251 and U87-TR/U87

    Neurochem Res, 2016, 41(12):3192-3205. Temozolomide purchased from Selleck.

产品安全说明书

DNA/RNA Synthesis抑制剂选择性比较

生物活性

产品描述 Temozolomide(TMZ)是一种单功能的SN-1烷化剂,修饰DNA环上的氮原子以及环外氧基团。在生理pH值下,TMZ转化为活性产物MTIC、降解为methyldiazonium cation,后者再将甲基转移到DNA, 阻碍DNA复制启动,诱使细胞凋亡,是一种DNA损伤诱导剂。
特性 Methazolastone是第二代烷化剂。
靶点
DNA replication [1]
(L-1210, L-1210/BCNU cells)
体外研究

Methazolastone引起DNA碱不稳定位点的形成,其在L-1210和L-1210/BCNU细胞系中以相似数量存在,并且以相似比率修复。在L-1210中,methazolastone诱导细胞阻滞在SL-G2-M期,但在L-1210/BCNU中无此作用。[1]对化疗敏感与耐受的细胞(D54-R 和 U87-R)对Methazolastone的敏感性在高氧情况下被显著增强。Methazolastone和高氧均与ERK p44/42 MAPK (Erk1/2)磷酸化的增加相关,但是在D54-R细胞中增加程度较低,表明Erk1/2可能参与高氧与Methazolastone介导的细胞死亡的调节。高氧增强Methazolastone诱导细胞凋亡在GBM细胞中产生的细胞毒性,可能是通过MAPK相关的途径发挥作用。[2] Methazolastone诱导单核细胞中DNA损伤应答通路ATM-Chk2 和ATR-Chk1,导致p53活化。[3]长期Methazolastone暴露导致获得性Methazolastone耐药,并提高miR-21表达。[4] Methazolastone治疗引起内质网(ER)应激,增加GADD153和GRP78蛋白质表达,并减少caspase 12前体蛋白质。Methazolastone通过线粒体损伤和内质网应激依赖机制诱导自吞噬,以保护神经胶质瘤细胞。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzmOFghcA>? M1qzeWlEPTB;MUO5MlIx6oDLwsJihKk2Njl3IN88US=> NEnSWZAzPTl4MEK4Ni=>
KellyCis83 MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[0PEBp NVrYfoFqUUN3ME2yOVEvODEkgJpCtgKBkTF3Lke1JO69VQ>? M{G2flI2QTZyMkiy
SK-N-AS NWnydHpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXG0PEBp NGfxfI1KSzVyPUKyO{44OOLCidMx5qCKOjJwMUWg{txO M2\YPVI2QTZyMkiy
SK-N-ASCis24 MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\K[|Q5KGh? M{XjNmlEPTB;NEiwMlYx6oDLwsJihKkyODFwMUWg{txO MU[yOVk3ODJ6Mh?=
CHP-212 M4Lub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXviTWN{PDhiaB?= M2\lUWlEPTB;Nz65O-KBkcLz4pEJNE43QSEQvF2= MUeyOVk3ODJ6Mh?=
CHP-212Cis100 NHvSco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ixOFQ5KGh? NVPHbWZwUUN3ME25MlU26oDLwsJihKkxNjh6IN88US=> MnLHNlU6PjB{OEK=
U87  M2TjW2Z2dmO2aX;uJGF{e2G7 MnrqNVAxKM7:TR?= MkKzNlQuPzJiaB?= M2qy[Ylv\HWlZYOgSINTOSCneIDy[ZN{cW:w Moe2NlU5ODh6Nki=
LN229 MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSwMVUxKM7:TR?= NWXU[pFMUUN3ME2xOkDPxE1? NYLoVpdPOjV5NUCyO|M>
TR-LN229 NIP4c5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHSOHQxNTVyIN88US=> NFnrRWVKSzVyPUe3JO69VQ>? NFKydZozPTd3MEK3Ny=>
U87  NY\4ZWVDSXCxcITvd4l{KEG|c3H5 NWPPbFdPOOLCk{KwNQKBkcL3TR?= NVfIbHpzOjRiaB?= NFP3TJpmdmijbnPld{BEWSCrbnT1Z4VlKGGyb4D0c5Nqew>? NWDQPIhjOjV4OEG2Olg>
U251MG MWnBdI9xfG:|aYOgRZN{[Xl? NFjnXlcyODEEoN88US=> MVi0PEBp NWPCV5doWEKV NGjxdZhqdmS3Y3XzJIFxd3C2b4Ppdy=> MVeyOVY5ODR4NB?=
U87MG MUfBdI9xfG:|aYOgRZN{[Xl? NHOxbHMyODEEoN88US=> Mn;ZOFghcA>? MnH4VGJU MYrpcoR2[2W|IHHwc5B1d3Orcx?= MmHZNlU3QDB2NkS=
U87 M1f1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnxXYZuPTBvM{WwJO69VQ>? MV[0POKhcMLi MXPpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> M2HQcVI2PTV2MkKz
U118  MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jw[|UxNTN3MDFOwG0> NXz5V2VqPDkEoHlCpC=> NG\ad|RqdmirYnn0d{Bk\WyuIHfyc5d1cCC|bHnnbJRtgQ>? MonVNlU2PTR{MkO=
U87 NVrnPY1oTnWwY4Tpc44hSXO|YYm= NXTvcndCOjVyL{O1NEDPxE1? M2nZRVQ5yqCqwrC= NIXWRZNmdmijbnPld{BVVVhvaX7keYNm\CCyLWDLR{1x[W5iZHXjdoVie2V? NGjVNo0zPTV3NEKyNy=>
U118  NFvTXJBHfW6ldHnvckBCe3OjeR?= NYO0O|BnOjVyL{O1NEDPxE1? NEjGcJo1QMLiaNMg M1nTT4VvcGGwY3XzJHROYC2rbnT1Z4VlKHBvUFvDMZBidiCmZXPy[YF{\Q>? NI\vNo0zPTV3NEKyNy=>
U87 MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;mb3kzPTBxM{WwJO69VQ>? MXm0POKhcMLi Mk\TbY5kemWjc3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGy|IHnuJHMh[W6mIFeyM23DqGOxdILlZZRm\CC5aYToJHROYA>? NIHic|AzPTV3NEKyNy=>
A375 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;oRVQ5yqCqwrC= MWTJR|UxRTJ4NTFOwG0> MmjTNlU2OjR3NUK=
A2058 NU\3UllXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknHOFjDqGkEoB?= MWfJR|UxRTF{IN88US=> NHjxbmgzPTV{NEW1Ni=>
M238 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYntPJR7PDkEoHlCpC=> Mn7vTWM2OD12MDFOwG0> NV;1cFZGOjV3MkS1OVI>
M249 MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX60POKhcMLi Mon0TWM2OD1{NUSg{txO M1zJSlI2PTJ2NUWy
M21 M3:4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjPOFjDqGkEoB?= NULZ[FJVUUN3ME2yNlEh|ryP NVj6OGFNOjV3MkS1OVI>
U251 M{npWWN6fG:2b4jpeJkhSXO|YYm= NEThfXczOCEQvF5CpC=> MlzkOFjDqGkEoB?= MYXy[YR2[2WmczD0bIUheGW{Y3XueIFo\XNib3[gZ49td26rZYOg[o9zdWWm NWrKOXA2OjV2M{SzPFE>
LN229 MUjDfZRwfG:6aYT5JGF{e2G7 MUKyNEDPxE4EoB?= NFHYfJg1QMLiaNMg MkewdoVlfWOnZIOgeIhmKHCncnPlcpRi\2W|IH;mJINwdG:waXXzJIZwem2nZB?= NVz4SWZsOjV2M{SzPFE>
U373MG-LUC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHjO|IhcA>? NFnUbWRKSzVyPk[wNEDPxE1? M3PQU|I2PDNzOUWz
U87  MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID5PJMzPS1{MECg{txO Mk[3OFjDqGkEoB?= MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MViyOVQxODd2NR?=
U251 NEHWXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSyOU0zODBizszN Mn\COFjDqGkEoB?= MmTKbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NIjNPYwzPTRyMEe0OS=>
U251 NXnofHdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHIZVYyODBvNECwJO69VQ>? MVe3Nk86PiCq MmPQeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi MnjxNlU{PzV{N{G=
U373 NGTDeXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrLNVAxNTRyMDFOwG0> NWjqOpV1PzJxOU[gbC=> NW\mcGFWfGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg NXztS3NjOjV|N{WyO|E>
U343 M4rFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXSNVAxNTRyMDFOwG0> M4DuUFczNzl4IHi= MU\0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? MnnLNlU{PzV{N{G=
U87MG-luc2 NF;OeWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\mSHdSOTByLUSwNEDPxE1? NHXlcHc4Oi97NjDo Mn2yeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi M{jMe|I2Ozd3Mkex
U87 MVPGeY5kfGmxbjDBd5NigQ>? M{L1U|IxOCEQvF2= M3\rbVQ5KGh? NUnhbndZcW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?= MWOyOVM{Pzd{MR?=
U251 MV3GeY5kfGmxbjDBd5NigQ>? MmXENlAxKM7:TR?= NYG0NFBPPDhiaB?= MV;pcoNz\WG|ZYOgRnJESzNibWLORUBmgHC{ZYPzbY9v NFTFbo4zPTN|N{eyNS=>
A172 MXHGeY5kfGmxbjDBd5NigQ>? MUWyNFAh|ryP NF3iWpc1QCCq MonEbY5kemWjc3XzJGJTS0N|IH3SUmEh\XiycnXzd4lwdg>? NFX2WmkzPTN|N{eyNS=>
U251 MlfVSpVv[3Srb36gRZN{[Xl? M1fBZlIxOCEQvF2= MUG0PEBp NYmwTmlOcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEKUQ1GxMEBDWkODMjygVmFFPTFiYX7kJGZCVkOGMh?= NHHj[HozPTN|N{eyNS=>
A172 MmP1SpVv[3Srb36gRZN{[Xl? NYTtd5lJOjByIN88US=> M{HJN|Q5KGh? NY\pXXV5cW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEKUQ1GxMEBDWkODMjygVmFFPTFiYX7kJGZCVkOGMh?= NFPOOY4zPTN|N{eyNS=>
U87 MoDwSpVv[3Srb36gRZN{[Xl? MnW3NlAxKM7:TR?= MnXvNlQwPzJxMUKwJIg> Mn\DbY5kemWjc3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdiC2aX3lMYRmeGWwZHXueIx6 MWOyOVM{Pzd{MR?=
U251 M3z1bWZ2dmO2aX;uJGF{e2G7 MW[yNFAh|ryP NYfi[YFvOjRxN{KvNVIxKGh? MXzpcoNz\WG|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk> NYjGbZlUOjV|M{e3NlE>
A172 M2Dv[GZ2dmO2aX;uJGF{e2G7 M3jZXlIxOCEQvF2= MkDYNlQwPzJxMUKwJIg> NH\BTW9qdmO{ZXHz[ZMh|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl? MWqyOVM{Pzd{MR?=
SNB19V MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPCO{Bl M17HdGROW09? MY\HTVUxRTN3LkhCtVEzKM7:TR?= MkTINlUzPzd2NEG=
SNB19M M{HTdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUG3JIQ> NFvKVpFFVVOR MWXHTVUxRTR4OT65xtE5QCEQvF2= MYeyOVI4PzR2MR?=
SNB19VR NX\JXmROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWm2RoI{PyCm Mle0SG1UVw>? NFvBNI5IUTVyPUK4NE4zyrFzODFOwG0> MVuyOVI4PzR2MR?=
U373V NV\ROZYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr4RWI4KGR? M33SdmROW09? NWfpdYJ4T0l3ME22PE4xyrF|MjFOwG0> NUHLfIdJOjV{N{e0OFE>
U373M NHm3[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTERldVPyCm M13HbWROW09? MWrHTVUxRTN4OD63xtE5PiEQvF2= MnTvNlUzPzd2NEG=
U373VR M1fIeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnhWIFPPyCm NELPdZFFVVOR MoGyS2k2OD1{OEiuPOKyOzNizszN MWiyOVI4PzR2MR?=
U87MG NGK2[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XGXFch\A>? MXPEUXNQ MWjHTVUxRTN6LkRCtVIxKM7:TR?= NF\tU2MzPTJ5N{S0NS=>
HCT116 MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYG3JIQ> NXfYUIJtTE2VTx?= MmDSS2k2OD13N{muPeKyOzJizszN MWKyOVI4PzR2MR?=
DLD1 Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrofpg4PyCm NXHzV5MzTE2VTx?= M2TyWWdKPTB;NUCxMlTDuTl|IN88US=> M3\mOFI2Ojd5NESx
MRC5 M1Xm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr3[3NlPyCm M13Dc2ROW09? Mo\GS2k2OD12NEmuOOKyQCEQvF2= NGrndGMzPTJ5N{S0NS=>
SNB19V  NWjYVJhETnWwY4Tpc44hSXO|YYm= MUKxNFAh|ryPwrDUUXo> NGLPNJUxNTd{IHi= MUXpcoNz\WG|ZYOg{tNJOkG[IHX4dJJme3Orb36gZoV1f2WnbjCxOkBidmRiN{KgbC=> NUfNbGJ1OjV{N{e0OFE>
T98G  Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljKOU8yOC9zNTFOwG0> MVGyOOKhcA>? MXXpcoR2[2W|IHPlcIwh\GWjdHig[I9{\S2mZYDlcoRmdnSueTDh[pRmeiClb37jc41qfGGwdD30[Y1wgm:ub33p[IUhf2m2aDDOVIU3NVCGVB?= NYjZcWxoOjV{NkK5OlE>
U251  M4jjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7BOU8yOC9zNTFOwG0> NXPiUXdNOjUEoHi= NI[xTWhqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZT3k[ZBmdmSnboTsfUBi\nSncjDjc45kd22rdHHueE11\W2xen;sc41q\GVid3n0bEBPWGV4LWDEWC=> MnvZNlUzPjJ7NkG=
T98G  M4KycWZ2dmO2aX;uJGF{e2G7 NV75R|ZTOTVizszN M1\Od|I1yqCq MnT0bY5kemWjc3XzJGRPSS2ocnHncYVvfGG2aX;uJIlvKE6SZU[tVGRVKHS{ZXH0[YQh\2yrb33hJINmdGy| MknvNlUzPjJ7NkG=
U251  NH3RVWhHfW6ldHnvckBCe3OjeR?= MlroNVUh|ryP MlrONlTDqGh? NHfXb41qdmO{ZXHz[ZMhTE6DLX\yZYdu\W62YYTpc44hcW5iTmDlOk1RTFRidILlZZRm\CCpbHnvcYEh[2WubIO= Ml;QNlUzPjJ7NkG=
U-87 MG MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG1UnA6PzJiaB?= MoXxTWM2OD1yLkmzJI1OyqB? NHX3dmQzPTJ2NUOzNi=>
U-118 MG NEfDN4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Kwc|czKGh? M3T0UGlEPTB;MT6wOUBuVcLi MnvpNlUzPDV|M{K=
U87 NWS4[YF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXmyOEBp M1\lXmlEPTB;Mk[wMlM1KM7:TdMg Mo\kNlUyPzN{M{O=
U87 GSLCs M2HQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSyOEBp NYHZdWJvUUN3ME23OlYvOTFizszNxsA> M4jzdFI2OTd|MkOz
U87MG M1[wPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jRZVczKGh? NYXodVU5UUN3ME2xOU43OjVizszNxsA> NX;vfGN7OjVyNUC5NVU>
U251 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[wNGMyODBvNECwJO69VQ>? NILvOJo1QCCq MXrEUXNQ M2X5d4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MleyNlQ3OjN5M{[=
U87 M{jWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuxNFAuPDByIN88US=> MX20PEBp NHfWS|hFVVOR NGPSTmZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUCyOFYzOzd|Nh?=
MDA-MB-231-br NULLXm8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr0NE0yOCEQvF2= NGnsZWQ1QCCq NILDU3pFVVOR MoPtbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Ml25NlQ3OjN5M{[=
HCC-1937 M3LZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOwMVMxOCEQvF2= MlLLOFghcA>? NGjBblhFVVOR NF3JRXNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2TOUVI1PjJ|N{O2
MDA-MB-231 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqwMVQxKM7:TR?= NH3iZWY1QCCq M4\BbmROW09? MmjEbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mkj0NlQ3OjN5M{[=
MDA-MB-468 MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;LUVAuPTByIN88US=> M1jueVQ5KGh? M3jiNGROW09? NHX4[GpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlvjNlQ3OjN5M{[=
T47D M{DVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\4U|AuOTByIN88US=> M3jaTVQ5KGh? MkLuSG1UVw>? M3PmUIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVmyOFYzOzd|Nh?=
MCF7 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj6fGwxNTFyMECg{txO NGnYclA1QCCq MVfEUXNQ NEDpVGRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mly3NlQ3OjN5M{[=
Hs683 NGPTfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXSWWUxNTFyMECg{txO NXfQd2tHQTZiaB?= NELjSnFKSzVyPUGyPE46KM7:TR?= MlLiNlQ1QTV7MEe=
U87 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHoUWtiOC1zMECwJO69VQ>? MVe5OkBp NEPtVVlKSzVyPUG4MlQ2KM7:TR?= NGDicIgzPDR7NUmwOy=>
LNZ308 NH\RTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSwMVExODBizszN MYq5OkBp NWH6[YR{UUN3ME2zNlYvPyEQvF2= MmTmNlQ1QTV7MEe=
U87 MU\BdI9xfG:|aYOgRZN{[Xl? M3LhcFExOCEQvF2= M3nqSlQ5KGh? MW\EUXNQ MoPUbY5kemWjc3XzJJRp\SClYYPwZZNmNTNxNzDhZ5Rqfmm2eR?= MoH2NlQ1QDF3OE[=
U251  MkX1RZBweHSxc3nzJGF{e2G7 M1rPVVExOCEQvF2= NUDLWFNyPDhiaB?= MmnBSG1UVw>? NYHTcFBxcW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=> NXvpSZdnOjR2OEG1PFY>
U251 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\xNlQhcA>? M4j0WmlEPTB;OE[uNlnjiIoEsfMAjVEvPThizszN MVyyOFMzPjl3NB?=
U251 MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTnbo01QCCq MXrJR|UxRTd3LkO05qCKyrIkgJmxMlAzKM7:TR?= MVKyOFMzPjl3NB?=
U251 MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXa[3Q1PzJiaB?= NX\ONJJqUUN3ME23Nk41OuLCidMx5qCKOS52NTFOwG0> NYDDNnNMOjR|Mk[5OVQ>
U251 MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7PNW46PiCq MmDCTWM2OD14OT64NwKBkcLz4pEJN{4xPCEQvF2= NHTpToMzPDN{Nkm1OC=>
T98G MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnDdJcxNTd3MDFOwG0> NXfXOpNSPzJxOU[gbC=> M1vzdolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MXyyOFMzPDB6MB?=
U251-MG M{jSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknpNE05ODBizszN NYHVZpJRPzJiaB?= NYnTfXRNcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M1j0PFI1ODl|NkOw
D54-MG NV:yN|VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUGwMVgxOCEQvF2= MnXyO|IhcA>? NGLLfmxqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NXjKdm1bOjRyOUO2N|A>
SHG-44 M3;3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHSV5B1OTBvMkCwJO69VQ>? NHHQWW46PiCq MnHBTWM2OD17LkezJOKyKDJwMUKg{txO M3PQcFI1ODZ3NU[5
U373  M{HP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[0NVAuOjByIN88US=> MXu5OkBp Mn\QTWM2OD1zMD6xN{DDuSBzLkCyJO69VQ>? NYfITFFIOjRyNkW1Olk>
HT-29  MVHGeY5kfGmxbjDBd5NigQ>? NFnyRW42ODBizszN MmHzNlQwPDhiaB?= NUewfXJX\W6qYX7j[ZMhfGinIHzleoVteyCxZjFOt{1JOkG[wrC= MUOyOFA{QDB4OB?=
PC-3  NGfYNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV6wMVI2KM7:TR?= NWHnR5ltPDhiaB?= NWjnTpYzcW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJJBwfGWwdHnheIVlKGK7IHz5Z49x\W6n MXWyN|c1Pjl|NB?=
PC-3  NHzUXGRCeG:ydH;zbZMhSXO|YYm= M4rVV|I2KM7:TR?= MXm0PEBp MWXpcoR2[2W|IHHwc5B1d3OrczD3bIlkcCClYX6gZoUheG:2ZX70bYF1\WRiYomgcJlkd3CnbnW= NFLoVIYzOzd2NkmzOC=>
T98G MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjq[2trPTBvNECwJO69VQ>? NWDNTGJNOTR2IHi= M2LkeYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MVOyN|cyPTR7OR?=
U87-MG NHuyNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H2T|ExOCEEtV2= MXu3NkBp Ml3mbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGdVSg>? MX2yN|Y6Pjd6OB?=
U251-MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor6NVAxKML3TR?= NHPh[pk4OiCq NIS2Sm5qdmirYnn0d{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWg[Y5p[W6lZXSgZpkhT1SE MVqyN|Y6Pjd6OB?=
LNT-229 M3y0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDiUHZpOy1zMECg{txO MVuyOEBp NXiwdJFIcW6qaXLpeJMh[2yxbn;n[Y5q[yC|dYL2bZZidCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MY[yN|Y3PzZ|Mh?=
T98G M{m4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvabpoyOC15MECg{txO M3[xT|I1KGh? MkLCbY5pcWKrdIOgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MUeyN|Y3PzZ|Mh?=
U87  MoHlSpVv[3Srb36gRZN{[Xl? NFXoeWIyODBiwsXN MkfFN{Bp NV7pS3BV\WyndnH0[ZMhfGinIHzleoVteyCxZjDwR4hsOSCjbnSgdGNpczJ? NGfUV4ozOzZ4N{S2PS=>
HCT116 M4fVdmZ2dmO2aX;uJGF{e2G7 M{OwRlExOCEEtV2= Mmi5N{Bp M2XBSYlv\HWlZYOgeIhmKEOqa{GgVIhwe3Cqb4L5cIF1cW:w MXuyN|Y3PzR4OR?=
HCT3-6 MlHNSpVv[3Srb36gRZN{[Xl? MUWxNFAhyrWP MYqzJIg> MUPpcoR2[2W|IITo[UBEcGtzIGDoc5NxcG:{eXzheIlwdg>? MVSyN|Y3PzR4OR?=
U-87  MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vrflAuPDBizszN NYmxb|l{OTJiZB?= M2\HXolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Ml7hNlM3PDV5Mkm=
U-87  MXnBdI9xfG:|aYOgRZN{[Xl? NXqxcHN[OC12MDFOwG0> Ml3oN{83KGR? NUX3XVlvcW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NVj2XXRDOjN4NEW3Nlk>
U-87  NIS2VXZHfW6ldHnvckBCe3OjeR?= M{LTVVAuPDBizszN NUnGTHZQOy94IHS= MoDubY5lfWOnczDheZRweGijZ4mgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NVrMWFh5OjN4NEW3Nlk>
GB-SCC010 NYPNNGdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLLW|Y1KGR? Ml:5TWM2OD1{Mk[g{txO Mn3RNlM3OTJ5NUW=
GB-SCC026 M1zqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C2c|Qh\A>? M1jTc2lEPTB;NUOuNUDPxE1? MUmyN|YyOjd3NR?=
GB-SCC028 NGX0XXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEi4dYU1KGR? M4XKSmlEPTB;MU[3JO69VQ>? MXKyN|YyOjd3NR?=
U87 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmCxOEBl NETiW41KSzVyPUS1MlIh|ryP MUCyN|YyOjd3NR?=
U87 stem cell M3PYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rN[FQh\A>? NHfJfoxKSzVyPU[2Mlch|ryP MWqyN|YyOjd3NR?=

... Click to View More Cell Line Experimental Data

体内研究 每天腹腔注射40 mg/kg,连续5天(肿瘤移植后1-5天)后,在L-1210 和L-1210/BCNU中,methazolastone分别增加86%和22%的寿命。在L-1210/BCNU中,100 μM 或200 μM治疗后没有作用,仅400 μM methazolastone使细胞在有丝分裂前期产生积聚,但是在L-1210中效果较弱。在L-1210/BCNU中,SL-G2-M期细胞的最大积聚在48-72小时后,大约为30%,未处理的细胞为23%。患有L- 1210白血病的小鼠静脉注射methazolastone (40 mg/kg)时,也会使细胞在SL-G2-M期积聚。而给予相同剂量药物的小鼠L-1210/BCNU细胞中,没有此作用。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

+ 展开
  • Cell lines: L-1210 和 L-1210/BCNU 细胞
  • Concentrations: 0 μM -100 μM
  • Incubation Time: 1小时
  • Method:

    L-1210和L-1210/ BCNU细胞以0.2×104 cells/mL接种,并培养24小时。培养基用Methazolastone在37℃下处理1小时,然后用PBS洗涤两次,离心并重新悬浮在新鲜培养基中。对照组和处理试样在48小时时以1:4在新鲜培养基中稀释,第96小时时,以1:2稀释。整个实验中使用这些稀释的细胞浓度介于3×105和8×105/mL之间。该范围内对照组呈对数生长。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 负荷L-1210 和 L-1210/BCNU细胞的DBA/2小鼠
  • Formulation: 95%乙醇
  • Dosages: 40 mg/kg
  • Administration: 静脉注射给药
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+ddH2O
2mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 194.15
化学式

C6H6N6O2

CAS号 85622-93-1
稳定性 powder
in solvent
别名 CCRG81045, NSC 362856

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03528642 Not yet recruiting Anaplastic Astrocytoma IDH-Mutant|Diffuse Astrocytoma IDH-Mutant|IDH1 Gene Mutation|IDH2 Gene Mutation National Cancer Institute (NCI) February 8 2019 Phase 1
NCT03709680 Not yet recruiting Solid Tumors|Ewing Sarcoma|Rhabdoid Tumor|Rhabdomyosarcoma|Neuroblastoma|Medulloblastoma Pfizer February 5 2019 Phase 1
NCT03688178 Not yet recruiting Glioblastoma Gary Archer Ph.D.|Duke University January 2019 Phase 2
NCT03732482 Not yet recruiting Non Small Cell Lung Cancer Metastatic Taizhou Hospital January 1 2019 Phase 2|Phase 3
NCT03607643 Not yet recruiting Cancer of Pancreas|Cancer of Liver|Cancer of Rectum|Cancer of Colon|Cancer Gall Bladder|Myeloma Multiple|Glioblastoma Multiforme Leaf Vertical Inc. January 15 2019 Phase 1|Phase 2
NCT03705351 Not yet recruiting Glioblastoma|Cancer of Brain|Glioblastoma Multiforme|Brain Tumor Providence Health & Services|Providence Health & Services Brain & Spine Institute|University of California San Francisco|NovoCure Ltd. December 1 2018 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

DNA/RNA Synthesis Signaling Pathway Map

相关DNA/RNA Synthesis产品

Tags: 购买Temozolomide | Temozolomide ic50 | Temozolomide价格 | Temozolomide DMSO溶解度 | 采购Temozolomide | Temozolomide生产 | Temozolomide 小鼠 | Temozolomide化学结构 | Temozolomide分子量 | Temozolomide molecular weight | Temozolomide说明书 | Temozolomide供应商 | Temozolomide体内 | Temozolomide细胞系 | Temozolomide浓度 | Temozolomide nmr | Temozolomide核磁 | Temozolomide半数抑制浓度 | Temozolomide体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID